194 related articles for article (PubMed ID: 1895443)
1. Regional chemotherapy using continuous intravesical infusion doxorubicin for the treatment of muscle invasive transitional cell bladder carcinoma in a rat model.
See WA; Xia Q; McDermott T; Williams RD
J Urol; 1991 Oct; 146(4):1147-52. PubMed ID: 1895443
[TBL] [Abstract][Full Text] [Related]
2. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity.
See WA; Xia Q
J Natl Cancer Inst; 1992 Apr; 84(7):510-5. PubMed ID: 1545441
[TBL] [Abstract][Full Text] [Related]
3. DPPG
Brummelhuis ISG; Simons M; Lindner LH; Kort S; de Jong S; Hossann M; Witjes JA; Oosterwijk E
Int J Hyperthermia; 2021; 38(1):1415-1424. PubMed ID: 34581259
[TBL] [Abstract][Full Text] [Related]
4. DPPG
van Valenberg FJP; Brummelhuis ISG; Lindner LH; Kuhnle F; Wedmann B; Schweizer P; Hossann M; Witjes JA; Oosterwijk E
Int J Nanomedicine; 2021; 16():75-88. PubMed ID: 33447028
[TBL] [Abstract][Full Text] [Related]
5. Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder.
Mross K; Maessen P; van der Vijgh WJ; Bogdanowicz JF; Kurth KH; Pinedo HM
Eur J Cancer Clin Oncol; 1987 May; 23(5):505-8. PubMed ID: 3477456
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
World J Urol; 2018 Nov; 36(11):1719-1725. PubMed ID: 29767328
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer.
Lu S; Xu L; Kang ET; Mahendran R; Chiong E; Neoh KG
Eur J Pharm Sci; 2016 Mar; 84():103-15. PubMed ID: 26780592
[TBL] [Abstract][Full Text] [Related]
8. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
9. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
Konety BR; Lavelle JP; Pirtskalaishvili G; Dhir R; Meyers SA; Nguyen TS; Hershberger P; Shurin MR; Johnson CS; Trump DL; Zeidel ML; Getzenberg RH
J Urol; 2001 Jan; 165(1):253-8. PubMed ID: 11125420
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation.
Qiu X; Cao K; Lin T; Chen W; Yuan A; Wu J; Hu Y; Guo H
Int J Nanomedicine; 2017; 12():7365-7374. PubMed ID: 29066888
[TBL] [Abstract][Full Text] [Related]
11. The fluorescence biodistribution and kinetics of aminolevulinic acid induced protoporphyrin IX in the bladder of a rat model with orthotopic urothelial carcinoma.
Gronlund-Pakkanen S; Wahlfors J; Makinen K; Pakkanen TM; Talja M; Ala-Opas M; Alhava E; Moore RB
J Urol; 2002 Apr; 167(4):1848-53. PubMed ID: 11912446
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravesical instillation of antitumor drugs in the development of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumors in rats.
Suzuki T; Imai K; Takezawa Y; Tsuji H; Yamanaka H; Suzuki K
Hinyokika Kiyo; 1989 Feb; 35(2):247-51. PubMed ID: 2735235
[TBL] [Abstract][Full Text] [Related]
14. Intravesical instillation of doxorubicin hydrochloride and its incorporation into bladder tumors.
Nakada T; Akiya T; Yoshikawa M; Koike H; Kayayama T
J Urol; 1985 Jul; 134(1):54-7. PubMed ID: 4009823
[TBL] [Abstract][Full Text] [Related]
15. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
Steinberg GD; Brendler CB; Squire RA; Isaacs JT
J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724
[TBL] [Abstract][Full Text] [Related]
16. The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations.
Arentsen HC; Hendricksen K; Hulsbergen-van de Kaa CA; Reddy G; Oosterwijk E; Alfred Witjes J
Urol Oncol; 2012; 30(1):64-8. PubMed ID: 19945311
[TBL] [Abstract][Full Text] [Related]
17. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
18. [Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy].
Koseki K; Irisawa C; Shiraiwa Y
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):268-73. PubMed ID: 1904118
[TBL] [Abstract][Full Text] [Related]
19. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma.
Garnick MB; Schade D; Israel M; Maxwell B; Richie JP
J Urol; 1984 Jan; 131(1):43-6. PubMed ID: 6690745
[TBL] [Abstract][Full Text] [Related]
20. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.
Long JP; Prout GR; Wong YK; Lin CW
J Urol; 1990 May; 143(5):1053-6. PubMed ID: 2329596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
